MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/jaha.125.045664

Медицинская библиотека · Journal of the American Heart Association · 2026

Long-Term Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Peripheral Artery Disease and Type 2 Diabetes.

Rosenzveig Akiva, Tefera Leben, Agrawal Ankit, Rajendran Judah, Massad Faysal, Badwan Osamah, Wajsberg Julia, Chaudhury Pulkit, Zidar David, Paul Timir K, Bhatt Deepak L, Nanjundappa Aravinda

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Peripheral artery disease (PAD) affects >236 million people globally, particularly among those with type 2 diabetes. GLP-1 (glucagon-like peptide-1) receptor agonists (GLP-1 RAs) offer cardiovascular and kidney benefits, but their impact on PAD-specific outcomes is underexplored. This study evaluates long-term GLP-1 RA effects on adverse outcomes in this population.

METHODS

A retrospective cohort study using the TriNetX platform (January 1, 2010-January 1, 2025) included patients with both PAD and type 2 diabetes prescribed either GLP-1 RAs or metformin, excluding those with recent cardiovascular events, end-stage renal disease, or prior amputations. Propensity score matching was performed to account for confounding. Outcomes at 5 years included mortality, myocardial infarction, hospitalization, stroke, revascularization, amputations, dialysis, major adverse cardiovascular events, and kidney events.

RESULTS

After matching, 2133 patients per cohort were analyzed in the overall group with PAD. At 5 years, GLP-1 RA therapy was associated with lower mortality (10.31% versus 14.49%; hazard ratio [HR], 0.74 [95% CI, 0.62-0.88]; P=0.0005), hospitalization (69.3% versus 74.7%; HR, 0.87 [95% CI, 0.81-0.94]; P=0.0002), revascularization (4.69% versus 7.27%; HR, 0.64 [95% CI, 0.50-0.82]; P=0.0004), major amputation (2.30% versus 4.36%; HR, 0.52 [95% CI, 0.37-0.74]; P=0.0002), and minor amputation (4.03% versus 6.42%; HR, 0.63 [95% CI, 0.48-0.83]; P=0.0007). major adverse cardiovascular events, myocardial infarction, stroke, and major adverse kidney events were similar between groups.

CONCLUSIONS

GLP-1 RAs were associated with lower rates of mortality, major amputation, revascularization, and hospitalization in PAD and type 2 diabetes patients. These findings support prioritizing GLP-1 RAs for limb-specific and cardiovascular outcomes in this high-risk group.

Для цитирования: Rosenzveig Akiva, Tefera Leben, Agrawal Ankit, Rajendran Judah, Massad Faysal, Badwan Osamah, Wajsberg Julia, Chaudhury Pulkit, Zidar David, Paul Timir K, Bhatt Deepak L, Nanjundappa Aravinda. Long-Term Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Peripheral Artery Disease and Type 2 Diabetes.. Journal of the American Heart Association. 2026. DOI: 10.1161/jaha.125.045664.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.